Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | THRB | P10828 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | PLG | P00747 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
| ▸ | FAAH | O00519 | 7/20 | 0.40 |
| ▸ | CES1 | P23141 | 5/20 | 0.40 |
| ▸ | CES2 | O00748 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18350804 | 1.00 | PAOX (0.56) | PAOXKMT2AMEN1LMNATHRB | |
| SCHEMBL13893493 | 1.00 | PAOX (0.56) | PAOXKMT2AMEN1LMNATHRB | |
| SCHEMBL13893494 | 1.00 | PAOX (0.56) | PAOXKMT2AMEN1LMNATHRB | |
| SCHEMBL16187339 | 0.98 | PAOX (0.52) | PAOXKMT2AMEN1LMNATHRB | |
| SCHEMBL10110819 | 0.90 | CYP1A2 (0.48) | PAOXKMT2AMEN1LMNATHRB | |
| SCHEMBL16722811 | 0.87 | FAAH (0.48) | KMT2AMEN1LMNAALDH1A1NFKB1 | |
| SCHEMBL16640758 | 0.87 | FAAH (0.48) | KMT2AMEN1LMNAALDH1A1NFKB1 | |
| SCHEMBL19163900 | 0.87 | FAAH (0.48) | KMT2AMEN1LMNAALDH1A1NFKB1 | |
| SCHEMBL13661862 | 0.87 | FAAH (0.48) | KMT2AMEN1LMNAALDH1A1NFKB1 | |
| SCHEMBL12247043 | 0.87 | FAAH (0.48) | KMT2AMEN1LMNAALDH1A1NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037355-B2 | Triterpene saponin analogues | ADJUVANCE TECHNOLOGIES, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20230263886-A1 | VACCINES, VACCINE PRIMING, AND ANTIGEN DOSE SPARING | ADJUVANCE TECHNOLOGIES, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230219991-A1 | TRITERPENE SAPONIN ANALOGUES | ADJUVANCE TECHNOLOGIES, INC. (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230183326-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | ASANA BIOSCIENCES, LLC | 2023-06-15 | — | — | US | disclosed |
| US-20230183326-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | ASANA BIOSCIENCES, LLC | 2023-06-15 | — | — | US | disclosed |
| US-20230174985-A1 | MODIFIED PEPTIDE NUCLEIC ACID COMPOSITIONS | NEUBASE THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230128815-A1 | ADJUVANT COMPOUNDS, SALT FORMS, AND FORMULATIONS | ADJUVANCE TECH INC (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230043447-A1 | PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20230021500-A1 | CYSTEINE ENGINEERED ANTIBODY-DRUG CONJUGATES WITH PEPTIDE-CONTAINING LINKERS | MERSANA THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20220409721-A1 | VARICELLA ZOSTER | ADJUVANCE TECHNOLOGIES, INC. (US) | 2022-12-29 | — | — | US | disclosed |
| US-8821850-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-8815226-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-20140134127-A1 | Protein-Polymer-Drug Conjugates | MERSANA THERAPEUTICS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140017265-A1 | Terminally Modified Polymers and Conjugates Thereof | MERSANA THERAPEUTICS, INC. | 2014-01-16 | — | — | US | disclosed |
| US-20130101546-A1 | Protein-Polymer-Drug Conjugates | MERSANA THERAPEUTICS, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-20100267757-A1 | AMINOTHIAZOLES AND THEIR USES | NOVARTIS AG (CH) | 2010-10-21 | — | — | US | disclosed |
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090105122-A1 | Selective neuropeptide y2 receptor agonists | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105122-A1 | Selective neuropeptide y2 receptor agonists | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267757-A1 | AMINOTHIAZOLES AND THEIR USES | ABAT, AADAT, GOT2 | PAOX 212/4885KMT2A 1982/4885MEN1 3821/4885 |
| US-20230219991-A1 | TRITERPENE SAPONIN ANALOGUES | LSS, NFATC1, PGGT1B | PAOX 161/4885KMT2A 4265/4885MEN1 4051/4885 |
| US-20140134127-A1 | Protein-Polymer-Drug Conjugates | PBRM1, CLTB, BRAP | PAOX 856/4885KMT2A 2203/4885MEN1 4707/4885 |
| US-20230128815-A1 | ADJUVANT COMPOUNDS, SALT FORMS, AND FORMULATIONS | MYD88, TLR7, NFATC1 | PAOX 204/4885KMT2A 2665/4885MEN1 2573/4885 |
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | ADCYAP1R1, VIPR2, ADCY2 | PAOX 1044/4885KMT2A 1853/4885MEN1 285/4885 |
| US-20230183326-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, STAMBP, TSPO | PAOX 614/4885KMT2A 1732/4885MEN1 2537/4885 |
| US-20140017265-A1 | Terminally Modified Polymers and Conjugates Thereof | MALT1, ALG1, PRMT3 | PAOX 2650/4885KMT2A 1139/4885MEN1 1055/4885 |
| US-20230021500-A1 | CYSTEINE ENGINEERED ANTIBODY-DRUG CONJUGATES WITH PEPTIDE-CONTAINING LINKERS | LNPEP, DNPEP, QPCT | PAOX 4757/4885KMT2A 2425/4885MEN1 1894/4885 |
| US-20230174985-A1 | MODIFIED PEPTIDE NUCLEIC ACID COMPOSITIONS | TARDBP, SARNP, SNRPE | PAOX 3744/4885KMT2A 2835/4885MEN1 2427/4885 |
| US-20230043447-A1 | PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES | CD2BP2, DNPEP, LNPEP | PAOX 4622/4885KMT2A 3687/4885MEN1 1711/4885 |
| US-20090105122-A1 | Selective neuropeptide y2 receptor agonists | NPY2R, NPY1R, NPY4R | PAOX 891/4885KMT2A 1579/4885MEN1 877/4885 |
| US-20220409721-A1 | VARICELLA ZOSTER | IFNG, HLA-DRB1, CXCL10 | PAOX 2893/4885KMT2A 4327/4885MEN1 4020/4885 |
| US-20230263886-A1 | VACCINES, VACCINE PRIMING, AND ANTIGEN DOSE SPARING | MYD88, CD14, DDOST | PAOX 1132/4885KMT2A 3509/4885MEN1 3138/4885 |
| US-12037355-B2 | Triterpene saponin analogues | LSS, NFATC1, PGGT1B | PAOX 161/4885KMT2A 4265/4885MEN1 4051/4885 |
| US-20130101546-A1 | Protein-Polymer-Drug Conjugates | PBRM1, CLTB, BRAP | PAOX 852/4885KMT2A 1978/4885MEN1 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.